The stock's rise snapped a four-day losing streak.

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

Shares of Biogen Inc. BIIB slumped 0.84% to $156.46 Monday, on what proved to be an all-around dismal trading session for the ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

US biotech major Biogen today announced the appointment of Tim Power as vice president, head of investor relations, effective immediately. Mr. Power will report to Michael McDonnell, executive VP and ...

Fintel reports that on December 9, 2024, Jefferies downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a high estimate of $300.00 and a low estimate of $180.00. Highlighting a 8.24 ...

In a report released today, Michael Yee from Jefferies downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...

Jefferies downgraded Biogen (BIIB) to Hold from Buy with a price target of $180, down from $250. The firm sees a “tough setup” into 2025 for Biogen with modest Leqembi and Skyclarys US. It see a “real ...